Aeglea Bio Therapeutics Analysis
| AGLEDelisted Stock | USD 0.59 0.01 1.72% |
Aeglea Bio Therapeutics is overvalued with Real Value of 0.42 and Hype Value of 0.59. The main objective of Aeglea Bio delisted stock analysis is to determine its intrinsic value, which is an estimate of what Aeglea Bio Therapeutics is worth, separate from its market price. There are two main types of Aeglea Bio's stock analysis: fundamental analysis and technical analysis.
The Aeglea Bio stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Aeglea Bio's ongoing operational relationships across important fundamental and technical indicators.
Aeglea |
Aeglea Stock Analysis Notes
About 98.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.35. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aeglea Bio Therapeutics recorded a loss per share of 74.15. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 8th of September 2023. Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas. Aeglea Biothera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 69 people. For more info on Aeglea Bio Therapeutics please contact James JD at 512 942 2935 or go to https://www.aeglea.com.Aeglea Bio Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more delisted stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Aeglea Bio's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Aeglea Bio Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Aeglea Bio is not yet fully synchronised with the market data | |
| Aeglea Bio has some characteristics of a very speculative penny stock | |
| Aeglea Bio has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.33 M. Net Loss for the year was (83.81 M) with loss before overhead, payroll, taxes, and interest of (262 K). | |
| Aeglea Bio Therapeutics currently holds about 73.68 M in cash with (80.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.2, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 98.0% of the company shares are held by institutions such as insurance companies |
Aeglea Bio Therapeutics Upcoming and Recent Events
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Aeglea Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 45.59 M.Aeglea Bio Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aeglea Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aeglea Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aeglea Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Stelzer Laurie over a year ago Acquisition by Stelzer Laurie of 50000 shares of Aeglea Bio subject to Rule 16b-3 | ||
Smith Hunter C over a year ago Acquisition by Smith Hunter C of 1950000 shares of Aeglea Bio subject to Rule 16b-3 |
Aeglea Bio Outstanding Bonds
Aeglea Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Aeglea Bio Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Aeglea bonds can be classified according to their maturity, which is the date when Aeglea Bio Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| US00775PAA57 Corp BondUS00775PAA57 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| AERCAP IRELAND CAP Corp BondUS00774MAG06 | View | |
| AERCAP IRELAND CAP Corp BondUS00774MAE57 | View | |
| AERCAP IRELAND CAP Corp BondUS00774MAC91 | View |
Aeglea Bio Predictive Daily Indicators
Aeglea Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Aeglea Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
About Aeglea Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Aeglea Bio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Aeglea shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as Aeglea Bio. By using and applying Aeglea Stock analysis, traders can create a robust methodology for identifying Aeglea entry and exit points for their positions.
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas. Aeglea Biothera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 69 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Aeglea Bio to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Economic Indicators Now
Economic IndicatorsTop statistical indicators that provide insights into how an economy is performing |
| All Next | Launch Module |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in Aeglea Stock
If you are still planning to invest in Aeglea Bio Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aeglea Bio's history and understand the potential risks before investing.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |